Trial
NCT03601507
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Arizona
Collaborators
National Cancer Institute (NCI)
Condition
CDKN2A-p16 Positive
Intervention
Alpelisib
Why stopped
Novartis has chosen to withdraw support for this trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-17